Diagnosing Polypoidal Choroidal Vasculopathy Without Indocyanine Green Angiography
Anti –vascular endothelial growth factor (VEGF) therapy is currently the standard of care for patients presenting with neovascular age-related macular degeneration (nAMD). Polypoidal choroidal vasculopathy (PCV) is an important subtype of nAMD, and is an underrecognized diagnosis in many parts of the w orld. Correctly diagnosing PCV is crucial because the treatment for PCV may differ from the usual treatment for nAMD. The EVEREST II study, a multicenter prospective clinical trial from many countries in Asia, showed better vision results with photodynamic therapy combined with anti-VEGF injections than with anti-VEGF monotherapy. These new findings require that PCV be better identified to provide the best care.
Source: JAMA Ophthalmology - Category: Opthalmology Source Type: research
More News: Age-Related Macular Degeneration (AMD) | Angiography | Clinical Trials | Opthalmology | Study